USE OF DOPAMINE D3 PARTIAL AGONISTS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS
申请人:BIOPROJET Pharma
公开号:EP3906927A1
公开(公告)日:2021-11-10
The present invention provides for the use of D3 partial agonists for treating or inhibiting the restless leg syndrome (RLS) and neurodegenerative diseases, in particular D3 partial agonists/D2 antagonists.
本发明提供了用于治疗或抑制不安腿综合征(RLS)和神经退行性疾病的 D3 部分激动剂,特别是 D3 部分激动剂/D2 拮抗剂。